BI Aims To ‘Own’ Indian Lung Cancer Space As Afatinib Debuts
This article was originally published in PharmAsia News
Executive Summary
"We want to own the lung cancer therapy space" is how Boehringer Ingelheim (BI) India's managing director Sharad Tyagi refers to the family-owned German multinational's ambitions in the segment following the introduction of afatinib, its first oncology product on the Indian market.